已收盘 02-06 16:00:00 美东时间
+3.810
+15.13%
Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driv...
01-30 23:36
BNAI飙涨276%,公司布局非洲人工智能市场;LE大涨33%,与WHP Global成立合资公司,释放品牌价值;坦桑尼亚黄金涨超21%,金价延续强势震荡走高>>
01-27 20:05
U.S. stocks were higher, with the Dow Jones gaining over 100 points on Monday. ...
01-27 01:05
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial.
01-22 23:59
BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to extend gains on Thu
01-22 22:11
BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its in-house AI chipmaking unit, T-Head. GLSI: 65% | Greenwich LifeSciences Says FDA Clears First Commercial
01-22 20:30
BUZZ-U.S. STOCKS ON THE MOVE-Micron, Rambus, GE Aerospace Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Thursday, signaling fresh buying momentum o
01-22 20:10
Gainers Greenwich LifeSciences (NASDAQ:GLSI) shares rose 48.6% to $33.13 durin...
01-22 20:05
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
01-22 19:02
Greenwich LifeSciences has received FDA approval to use the first commercial GP2 batch in its FLAMINGO-01 Phase III trial for preventing breast cancer recurrences. Three commercial batches were manufactured in 2023 and 2024, with stability data supporting a 3-year shelf life. The company plans to begin using the new GP2 vials across all 40 US trial sites soon. This approval de-risks BLA filing in the US, with further manufacturing and clinical da...
01-22 11:00